Table 6.
Activity of antimicrobial agents tested against 545 Pseudomonas isolates from intra-abdominal infections.
| Activity of antimicrobial agents tested against 545 Pseudomonas isolates from intra-abdominal infections in the SENTRY program collected during 2019, 2020, and 2021 | |||||||||||
| Organisms include: Pseudomonas aeruginosa (529), P. citronellolis (1), P. fluorescens group (1), P. koreensis (1), P. oryzihabitans (1), P. plecoglossicida (1), P. protegens (2), P. putida group (4), P. stutzeri (3), unspeciated Pseudomonas (2) | |||||||||||
| Antimicrobial Agent | Continent | Count | MIC50 | MIC90 | Range | CLSI | EUCAST | ||||
| S (%) | I (%) | R (%) | S (%) | I (%) | R (%) | ||||||
| Imipenem | All | 544 | 1 | 8 | ≤0.12 to >8 | 80.5 | 4.4 | 15.1 | 0 | 0 | 0 |
| Asia-W. Pacific | 138 | 1 | 8 | ≤0.12 to >8 | 86.2 | 2.2 | 11.6 | 0 | 0 | 0 | |
| Europe | 184 | 1 | 8 | ≤0.12 to >8 | 76.1 | 7.6 | 16.3 | 0 | 0 | 0 | |
| Latin America | 52 | 1 | >8 | ≤0.12 to >8 | 76.9 | 1.9 | 21.2 | 0 | 0 | 0 | |
| North America | 170 | 1 | 8 | ≤0.12 to >8 | 81.8 | 3.5 | 14.7 | 0 | 0 | 0 | |
| Meropenem | All | 541 | 0.5 | 8 | ≤0.015 to >32 | 83.9 | 4.3 | 11.8 | 83.4 | 9.4 | 7.2 |
| Asia-W. Pacific | 138 | 0.25 | 8 | ≤0.015 to >32 | 88.4 | 0.7 | 10.9 | 88.4 | 5.1 | 6.5 | |
| Europe | 182 | 0.5 | 8 | ≤0.015 to 32 | 81.3 | 6.6 | 12.1 | 81.3 | 12.6 | 6.0 | |
| Latin America | 50 | 0.5 | 16 | 0.03 to >32 | 78.0 | 6.0 | 16.0 | 78.0 | 10.0 | 12.0 | |
| North America | 171 | 0.5 | 8 | 0.03 to >32 | 84.8 | 4.1 | 11.1 | 83.0 | 9.4 | 7.6 | |
Abbreviations (MIC50 and MIC90: the lowest concentration of the antibiotic at which 50 and 90% of the isolates were inhibited; CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; S (%) percentage of susceptible pathogens, evidenced in green; I (%) percentace of pathogens with intermediate susceptibility, evidenced in yellow; R (%) percentage of resistant pathogens, evidenced in red).